HuidaGene Secures Rare Pediatric Disease Designation for CRISPR Therapy HG302 Targeting DMD
HuidaGene Therapeutics, based in China, has announced that it has received Rare Pediatric Disease Designation...
Drug
HighField Biopharmaceutical Doses First Patient in HFK1 Clinical Trial Targeting Solid Tumors
Hangzhou-based HighField Biopharmaceutical, a leader in immuno-oncology focused on innovative lipid-based therapies, has announced the...
EMA’s CHMP Gives Green Light to Sanofi’s Fexinidazole for Acute Sleeping Sickness Treatment
Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
InventisBio’s KRAS G12C Inhibitor D-1553 Advances Toward Priority Review in China
According to the China Center for Drug Evaluation (CDE), Shanghai-based InventisBio Co., Ltd. (SHA: 688382)...
Keytruda Gains 12th Indication Approval in China for HER2-Negative Gastric Cancer
US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its immunotherapy...
Sirnaomics Ltd Granted FDA Approval for Phase I RSV mRNA Vaccine Study
Sirnaomics Ltd (HKG: 2257) has received approval from the US Food and Drug Administration (FDA)...
Roche Receives NMPA Approval for Ophthalmology BsAb Vabysmo (Farcimab) for Diabetic Macular Edema
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has obtained marketing approval from...
Huadong Medicine Gets NMPA Green Light for Clinical Study of Ryzodeg Biosimilar
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
FDA Approves Pfizer-Astellas-MSD Combo Therapy for Advanced Urothelial Cancer
Pfizer (NYSE: PFE), Astellas (TYO: 4503), and Merck, Sharp & Dohme (MSD; NYSE: MRK) have...
Bio-Thera Solutions Gets NMPA Green Light for PD-1 Inhibitor BAT1308 in Endometrial Cancer
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
Sanofi’s Rezurock Secures Marketing Approval in China for Chronic Graft-vs-Host Disease
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that its drug Rezurock (belumosudil), the world’s...
InnoCare’s TYK2 Inhibitor ICP-332 Shows Positive Results in Atopic Dermatitis Phase II Study
Beijing InnoCare Pharma Tech Co., (HKG: 9969), a Chinese biotechnology company specializing in oncology and...
MSD’s Welireg Gains FDA Approval for Advanced Renal Cell Carcinoma
The US Food and Drug Administration (FDA) has granted an indication extension approval for Merck,...
3D Medicines Initiates Phase III Trial for Envafolimab in NSCLC Patient
3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the enrollment of the first...
Sino Biopharmaceutical Submits Market Approval Application for Recombinant Coagulation Factor VIIa
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
Lepu Biotechnology’s Pancreatic Cancer Drug Earns Orphan Drug Status from FDA
Lepu Biotechnology Co., Ltd (HKG: 2157), a Chinese pharmaceutical company, has announced that it has...
AbbVie and Genmab’s Epcoritamab Shows Promising Results in Follicular Lymphoma Study
AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have presented Phase I/II clinical data for their...
Amgen’s Tarlatamab Receives FDA Priority Review for Advanced Small Cell Lung Cancer Treatment
The US Food and Drug Administration (FDA) has granted priority review status to Amgen (NASDAQ:...
Eisai and BioArctic Set December Launch for Alzheimer’s Drug Leqembi in Japan
Eisai (TYO: 4523) and BioArctic (STO: BIOA-B) have announced the launch of Leqembi (lecanemab) in...
Abbisko Therapeutics’ Pimicotinib Earns FDA Fast-Track Status for TGCT Treatment
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology firm, has announced that its colony...